Almirall

ALMIRALL NEWSROOM (3 press releases)

Advanced Filtering & Sorting Options:

Archive by Year: All 2025 2024 2023 2022 2021 2020 2016 2014 2013

Almirall arbeitet mit Ablexis und AlivaMab Discovery Services zusammen, um seine Entwicklungsbemühungen für innovative Behandlungsoptionen für Patienten mit schweren Hauterkrankungen zu beschleunigen

PRESS RELEASE -- 31, January 2022

Durch diese Lizenzvereinbarung mit Ablexis erhält Almirall Rechte zur Nutzung der AlivaMab®-Maustechnologie für die Forschung, Entwicklung und Vermarktung von Antikörpern AlivaMab Mouse bietet hochmoderne transgene Mausplattformen, die humane therapeutische Antikörper mit hoher Vielfalt liefern Almirall wird mit AlivaMab Discovery Services … Read the full press release →

Almirall partners with Ablexis and AlivaMab Discovery Services to accelerate its development efforts for innovative treatment options for patients suffering from severe skin diseases

PRESS RELEASE -- 31, January 2022

Through this license agreement with Ablexis, Almirall is granted rights to use the AlivaMab® Mouse technology for research, development, and commercialisation of antibodies AlivaMab Mouse offers state-of-the-art transgenic mouse platforms delivering highdiversity human therapeutic antibodies Almirall will partner with AlivaMab … Read the full press release →

AstraZeneca completes the transfer of Eklira/Tudorza and Duaklir global rights to Covis Pharma Group for $270 million

PRESS RELEASE -- 5, January 2022

(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of the transfer of its global rights to Eklira (aclidinium bromide), popular as Tudorza in the US, and Duaklir … Read the full press release →